Article

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

2023-12-08

Abstract excerpt

<h4>Summary</h4> Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor specimens along with normal tissues to identify biologically relevant cell surface proteins that can serve as immunotherapeutic targets for neuroblast...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62b8d738-ed4a-5e13-a990-9e0472c80e64
DOI: 10.1101/2023.12.06.570390

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaDOI 10.1101/2023.12.06.570390Read

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaSemantic proximity Read

Molecular mechanisms and therapeutic targets in neuroblastomaSemantic proximity Read

The Target Atlas for Antibody-Drug Conjugates across Solid CancersSemantic proximity Read

PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in NeuroblastomaSemantic proximity Read

Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles.Semantic proximity Read

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read

Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.Semantic proximity Read

The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapiesSemantic proximity Read

Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppressionSemantic proximity Read

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapySemantic proximity Read

Pan-cancer proteogenomics expands the landscape of therapeutic targetsSemantic proximity Read

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacySemantic proximity Read